Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7826768 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBSIGMAR1S1PR5DRD4 | |
| SCHEMBL7827240 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBSIGMAR1S1PR5DRD4 | |
| SCHEMBL8329828 | 0.85 | POLB (0.59) | SMN1; SMN2POLBSIGMAR1S1PR5KCNH2 | |
| SCHEMBL4034621 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBSIGMAR1S1PR5KCNH2 | |
| SCHEMBL3614165 | 0.78 | CCR3 (0.50) | SMN1; SMN2POLBSIGMAR1S1PR5S1PR1 | |
| SCHEMBL25081078 | 0.77 | FUCA1 (0.56) | SIGMAR1S1PR5S1PR1ALDH1A1 | |
| SCHEMBL16461078 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBSIGMAR1S1PR5S1PR1 | |
| SCHEMBL1809499 | 0.76 | DRD4 (0.65) | SMN1; SMN2POLBSIGMAR1DRD4 | |
| SCHEMBL4031677 | 0.76 | DRD4 (0.65) | SMN1; SMN2POLBSIGMAR1DRD4 | |
| SCHEMBL4026839 | 0.76 | DRD4 (0.65) | SMN1; SMN2POLBSIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691841-B2 | Azetidine derivatives as CCR-3 receptor antagonist | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| EP-1781606-B1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20070259848-A1 | Azetidine Derivatives as Ccr-e Receptor | NOVARTIS AG (CH) | 2007-11-08 | — | — | US | disclosed |
| EP-1781606-A2 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015854-A2 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259848-A1 | Azetidine Derivatives as Ccr-e Receptor | CCR1, CCR3, CCR9 | SMN1; SMN2 3181/4885POLB 4420/4885SIGMAR1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.